Biomarkers of CASH

Description

The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.

Conditions

Cerebral Cavernous Malformation, Cavernous Angioma, Hemorrhagic Microangiopathy

Talk to us

Study Overview

On this page

Study Details

Study overview

The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.

Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)

Biomarkers of CASH

Condition
Cerebral Cavernous Malformation
Intervention / Treatment

-

Contacts and Locations

Phoenix

Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States, 85013

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94117

Chicago

The University of Chicago Medical Center, Chicago, Illinois, United States, 60637

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Clinical diagnosis of CA
  • 2. age 18 or older
  • 3. solitary or multiple
  • 4. familial or sporadic
  • 5. with or without prior symptoms
  • 1. Prior excision of a solitary CA lesion
  • 2. prior stereotactic radiosurgery or any brain irradiation
  • 3. spinal cavernoma without brain lesion
  • 4. other brain pathology unrelated to CA (demyelinating disease, brain tumor)
  • 5. seizures or stroke unrelated to CA in the prior year
  • 6. current pregnancy or within 6 months postpartum
  • 7. reluctance to undergo venipuncture or donate blood specimen, or be called for clinical follow-up for up to one year
  • 8. homeless or incarcerated persons, or other reason a subject will be unable/unlikely to be reached for follow-up

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Chicago,

Issam Awad, MD, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

2026-06-30